**Clinical details**

<table>
<thead>
<tr>
<th>S1.02</th>
<th>Clinical information on request form</th>
<th>Not provided OR Text OR Structured entry as below:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>*Operative procedure</td>
<td>See p2</td>
</tr>
<tr>
<td></td>
<td>Neoadjuvant therapy</td>
<td>See p2</td>
</tr>
<tr>
<td></td>
<td>Recurrence</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Recurrence - regional, describe</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Recurrence - distant, describe</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Laterality</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Not specified OR Right OR Left OR Bilateral OR Other, specify</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Previous treatment</td>
<td>Text</td>
</tr>
</tbody>
</table>

**Microscopic findings**

<table>
<thead>
<tr>
<th>S3.01</th>
<th>*Histological tumour type</th>
<th>See p2</th>
</tr>
</thead>
<tbody>
<tr>
<td>G3.01</td>
<td>*Primary tumour site</td>
<td>Not specified/unknown Specify site (e.g., oral cavity, larynx)</td>
</tr>
<tr>
<td>S3.02</td>
<td>Lymph node laterality</td>
<td>Not specified OR Right OR Left OR Central OR Other, specify</td>
</tr>
</tbody>
</table>

**S3.03**

- *LYMPH NODE STATUS*
  - *Node level*
  - *Number of nodes examined* See p2
  - *Number of nodes positive* OR Cannot be determined
  - *Maximum dimension of largest lymph node metastasis* (if applicable) __ mm
  - *Maximum dimension of largest involved lymph node* (if applicable) __ mm AND Specify site (level)
  - *Soft tissue metastasis* Not identified/unknown

<table>
<thead>
<tr>
<th>G3.02</th>
<th>Number of nodes with ENE</th>
<th>__ mm OR Cannot be determined</th>
</tr>
</thead>
<tbody>
<tr>
<td>G3.03</td>
<td><em>Greatest extent of ENE</em></td>
<td>__ mm AND Specify site (level)</td>
</tr>
<tr>
<td>G3.04</td>
<td><em>Non-lymphatic structures involved</em> Not identified/unknown Specify site (level)</td>
<td></td>
</tr>
<tr>
<td>G3.05</td>
<td><em>MARGIN STATUS - perinodal surgical margin</em> See p2</td>
<td></td>
</tr>
</tbody>
</table>

**Ancillary test findings**

| G4.01 | *Ancillary studies* See p3 |

---

**Macroscopic findings**

<table>
<thead>
<tr>
<th>S2.01</th>
<th>Specimen labelled as</th>
<th>Text</th>
</tr>
</thead>
<tbody>
<tr>
<td>S2.02</td>
<td>Specimen laterality</td>
<td>Not specified OR Right OR Left OR Bilateral OR Other, specify</td>
</tr>
<tr>
<td></td>
<td>Specimen submitted</td>
<td>See p2</td>
</tr>
<tr>
<td>G2.01</td>
<td><em>Operative procedure</em></td>
<td>See p2</td>
</tr>
<tr>
<td>G2.02</td>
<td>Specimen dimensions</td>
<td>__ x __ x __ mm Notes: Record measurements for each specimen submitted</td>
</tr>
<tr>
<td>G2.03</td>
<td>Number of lymph nodes retrieved</td>
<td>__ Note: Record number for each lymph node site submitted</td>
</tr>
<tr>
<td>G2.04</td>
<td>Macroscopic metastatic tumour</td>
<td>Not identified/unknown</td>
</tr>
<tr>
<td>G2.05</td>
<td>Maximum dimension of largest metastatic deposit</td>
<td>__ mm</td>
</tr>
<tr>
<td>G2.06</td>
<td>Macroscopic evidence of extracapsular spread</td>
<td>Absent/ Present</td>
</tr>
<tr>
<td>G2.07</td>
<td>Macroscopic distance of tumour to closest margin</td>
<td>__ mm</td>
</tr>
<tr>
<td>S2.04</td>
<td>Ink application and block identification key</td>
<td>Text</td>
</tr>
<tr>
<td>G2.08</td>
<td>Additional macroscopic comments</td>
<td>Text</td>
</tr>
</tbody>
</table>

**Ancillary test findings**

| G4.01 | *Ancillary studies* See p3 |

---

V1.0 Guide derived from Nodal Excisions and Neck Dissection Specimens for Head & Neck Tumours Structured Reporting Protocol 1st Edition
## S3.01 Histological Tumour Type

### Sqamous cell carcinoma (SCC)
- Squamous cell carcinoma, conventional
- HPV-mediated/p16 positive oropharyngeal carcinoma
- Basaloid squamous cell carcinoma
- Papillary squamous cell carcinoma
- Spindle cell squamous cell carcinoma (sarcomatoid carcinoma)
- Adenosquamous cell carcinoma
- Acantholytic squamous cell carcinoma
- Carcinoma cuniculatum

### Salivary gland carcinoma
- Acinic cell carcinoma
- Secretory carcinoma
- Mucoepidermoid carcinoma
  - Low grade mucoepidermoid carcinoma
  - Intermediate grade mucoepidermoid carcinoma
  - High grade mucoepidermoid carcinoma
- Adenoid cystic carcinoma
  - Tubular/cribriform pattern predominant
  - Solid pattern >30%
- Polymorphous adenocarcinoma
  - Classic, specify grade
  - Cribriform
- Epithelial-myoepithelial carcinoma
- (Hyalinizing) Clear cell carcinoma
- Basal cell adenocarcinoma
- Sebaceous adenocarcinoma
- Cystadenocarcinoma
- Adenocarcinoma, not otherwise specified (NOS)
- Salivary duct carcinoma
- Myoepithelial carcinoma
- Carcinoma ex pleomorphic adenoma, specify types
- Carcinosarcoma
- Poorly differentiated carcinoma: Neuroendocrine and non-neuroendocrine
  - Undifferentiated carcinoma
  - Large cell neuroendocrine carcinoma
  - Small cell neuroendocrine carcinoma
  - Lymphoepithelial carcinoma
  - Squamous cell carcinoma
  - Oncocytic carcinoma
- Other, specify

### Neuroendocrine carcinoma
- Well differentiated (typical carcinoid)
- Moderately differentiated (atypical carcinoid)
- Poorly differentiated (high grade neuroendocrine carcinoma), large cell type
- Poorly differentiated (high grade neuroendocrine carcinoma), small cell type

### Nasopharyngeal carcinoma
- Squamous cell carcinoma, keratinizing
- Squamous cell carcinoma, non-keratinizing, differentiated
- Squamous cell carcinoma, non-keratinizing, undifferentiated
- Squamous cell carcinoma, basoloid
- Nasopharyngeal papillary adenocarcinoma

### Sinonasal malignancies
- Mucosal melanoma
- Cutaneous malignancies
  - Melanoma
  - Squamous cell carcinoma
  - Merkel cell carcinoma
- Sebaceous carcinoma

### Other, specify types

### S3.03 Lymph node status

Select all that apply:
- Level IA
- Level IB
- Level II
- Level III
- Level IV
- Level V
- Level VI
- Level VII
- Levels I-IV
- Levels I-V
- Other, specify

### Notes:
Specimen laterality should be recorded for each specimen submitted (S2.02).
S3.05 Margin status
- perinodal surgical margin
  • Not involved by carcinoma
  • Involved by carcinoma
    ◊ Right
    ◊ Left
    ◊ Central
    ◊ Laterality not specified
  • Cannot be assessed, specify

S5.01 Pathological staging
(AJCC 8th Edition)

**TNM descriptors**

- y - post therapy; r - recurrent

For primary carcinomas of the lip and oral cavity, major salivary glands, nasal cavity and paranasal sinuses, oropharynx (p16 negative), hypopharynx, larynx, cutaneous head and neck carcinomas (with the exception of Merkel cell carcinoma) and unknown primary squamous cell carcinomas that are p16 and EBV-negative. Cutaneous squamous cell carcinoma of the head and neck also included.

NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-)
N2 Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+);
  or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-);
  or metastasis in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-);
  or bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-)
N2a Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+);
  or a single ipsilateral lymph nodes, none larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-)
N2b Metastasis in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-)
N2c Metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-)
N3 Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-);
  or in a single ipsilatery lymph node larger than 3 cm in greatest dimension and ENE(+);
  or multiple ipsilateral, contralateral or bilateral nodes any with ENE(+)
N3a Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-);
N3b Metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+);
  or multiple ipsilateral, contralateral or bilateral nodes any with ENE(+)

HPV-mediated (p16+) oropharyngeal carcinoma

NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in 4 or fewer lymph node(s)
N2 Metastasis in more than 4 lymph node(s)

Cutaneous melanoma

NX Regional nodes not assessed
N0 No regional lymph node metastases
N1 Metastasis in one regional lymph node or intralymphatic regional metastasis without nodal metastases
N1a Only microscopic metastasis (clinically occult)
N1b Macroscopic metastasis (clinically apparent)
N1c Satellite or in-transit metastasis without regional nodal metastasis
N2 Metastasis in two or three regional lymph nodes or intralymphatic regional metastasis with lymph node metastases
N2a Only microscopic nodal metastasis
N2b Macroscopic nodal metastasis
N2c Satellite or in-transit metastasis with one regional nodal metastasis
N3 Metastasis in four or more regional lymph nodes, of matted metastatic regional lymph nodes, or satellite(s) or in-transit metastasis with metastasis in two or more regional lymph node(s)
N3a Only microscopic nodal metastasis
N3b Macroscopic nodal metastasis
N3c Satellite or in-transit metastasis with two or more regional nodal metastasis

Note: Add stage information for Merkel cell carcinoma when distinct form head and neck cutaneous SCC.

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Eighth Edition (2016) published by Springer Science and Business Media LLC, www.springerlink.com